Publications by authors named "M McClung"
The 24 Annual Santa Fe Bone Symposium (SFBS) was held in Santa Fe, New Mexico, USA, on August 2-3, 2024. This was a "hybrid" meeting, with in-person and real-time remote participants representing a broad range of geographical locations and medical disciplines. The focus was on new developments in the care of patients with osteoporosis, other metabolic bone diseases, and inherited skeletal disorders.
View Article and Find Full Text PDFBone mineral density (BMD) is only one of several bone strength determinants affected by osteoporosis therapies. Trabecular Bone Score (TBS), a gray-level texture index determined from lumbar spine (LS) dual-X-ray absorptiometry scans, is an indirect measure of bone microarchitecture independent of and complementary to BMD and clinical risk factors. In the ARCH study, monthly subcutaneous romosozumab 210 mg for 12 months followed by 24-month open-label weekly oral alendronate 70 mg (romosozumab-to-alendronate) significantly reduced fracture risk compared to 36-month alendronate alone in postmenopausal women with osteoporosis and prior fracture.
View Article and Find Full Text PDFGuidelines for the correct use of the nomenclature of biochemical indices of bone status: a position statement of the Joint IOF Working Group and IFCC Committee on Bone Metabolism.
Clin Chem Lab Med
November 2024
Article Synopsis
- - The guidelines update the International Osteoporosis Foundation's (IOF) 20-year-old position paper on bone markers, reflecting advancements in bone biology and disorders.
- - The authors introduce a new classification called Bone Status Indices (BSI) to replace outdated terms like bone turnover markers and metabolic markers for better clarity.
- - The proposal includes standardized nomenclature, abbreviations, and measurement units for these indices to ensure consistency in the study and treatment of bone health.
Romosozumab for the treatment of osteoporosis - a systematic review.
J Endocrinol Invest
November 2024
Introduction: Romosozumab, a new treatment of osteoporosis, is a monoclonal antibody that targets sclerostin and thereby exhibits a dual mechanism of action by stimulating bone formation and inhibiting bone resorption. This systematic review aims to assess the clinical efficacy and safety of romosozumab for treatment of primary and secondary osteoporosis.
Methods: A comprehensive literature search was conducted in October 2023 across multiple databases including Embase, PubMed and Cochrane Library.
Osteopenia was originally a qualitative term denoting bone that appeared to be less dense on radiographs. Since 1994, it has also had the quantitative meaning of a bone mineral density (BMD) T-score between -1·0 and -2·5. More than 60% of White women older than 64 years are osteopenic.
View Article and Find Full Text PDF